Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HARMONYL vs ALDOCLOR-250
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Harmonyl is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, leading to decreased peripheral vascular resistance and blood pressure.
Aldoclor-250 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urinary output and reducing plasma volume.
Hypertension (FDA-approved),Off-label: Management of opioid withdrawal symptoms, treatment of attention deficit hyperactivity disorder (ADHD), and reduction of menopausal hot flashes
Hypertension (first-line or adjunctive therapy),Off-label: Management of hypertensive crisis (as part of combination therapy)
25 mg orally once daily, taken with food. Maximum dose: 50 mg once daily.
250 mg orally twice daily
Terminal half-life: 12–18 hours (mean 15 h); extends to 24–30 h in hepatic impairment
1.5-3 hours; prolonged in renal impairment (up to 20 hours with Cr Cl <10 m L/min).
Hepatic metabolism via glucuronidation and sulfation; CYP450 enzymes not significantly involved.
Methyldopa: Primarily hepatic metabolism via catecholamine pathways; conjugated to sulfate and other metabolites. Chlorothiazide: Not extensively metabolized; excreted unchanged in urine.
Renal: 70% as unchanged drug; Biliary/fecal: 20% as metabolites; 10% other
Renal (70-80% unchanged), biliary/fecal (15-25% as metabolites); total clearance ~250 m L/min.
95% bound primarily to albumin and alpha-1-acid glycoprotein
25-40% bound primarily to albumin and alpha-1-acid glycoprotein.
1.2–1.8 L/kg (mean 1.5 L/kg); indicates extensive tissue distribution
0.6-1.0 L/kg; indicates distribution into total body water and some tissue binding.
Oral: 75%; IM: 90%
70-90% (oral); 100% (IV).
GFR ≥ 30 m L/min: no adjustment. GFR 15-29 m L/min: reduce to 12.5 mg once daily. GFR < 15 m L/min: not recommended.
Cr Cl >50 m L/min: no adjustment; Cr Cl 10-50 m L/min: 250 mg once daily; Cr Cl <10 m L/min: 250 mg every 48 hours
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose to 12.5 mg once daily. Child-Pugh C: contraindicated.
Child-Pugh A: no adjustment; Child-Pugh B: use with caution, reduce dose by 50%; Child-Pugh C: avoid use
Weight < 30 kg: not established. Weight ≥ 30 kg: 0.5 mg/kg orally once daily, up to 25 mg maximum.
Not recommended for use in pediatric patients due to lack of safety and efficacy data
Initiate at 12.5 mg once daily; increase cautiously to 25 mg once daily based on tolerability and renal function.
Start at lower end of dosing range; monitor renal function closely; adjust dose based on Cr Cl
Abrupt discontinuation may cause rapid rise in blood pressure (rebound hypertension) and symptoms of sympathetic overactivity (e.g., nervousness, agitation, headache). This is particularly dangerous in patients on high doses or concurrent beta-blocker therapy.
None explicitly listed. However, methyldopa carries a warning for hepatotoxicity and hemolytic anemia; chlorothiazide carries a warning for electrolyte disturbances and hypersensitivity reactions.
Rebound hypertension upon abrupt withdrawal; caution in patients with severe coronary insufficiency, recent myocardial infarction, cerebrovascular disease, or chronic renal failure; may cause sedation and dry mouth; use caution in patients with history of depression.
Hepatotoxicity (methyldopa), hemolytic anemia, positive direct Coombs test, sedation, depression, bradycardia, orthostatic hypotension, electrolyte imbalance (hypokalemia, hyponatremia, hypomagnesemia), hyperuricemia, hyperglycemia, photosensitivity, lupus-like syndrome, and hypersensitivity reactions.
Hypersensitivity to clonidine or any component; use with MAO inhibitors (hypertensive crisis risk); noncompliant patients who may abruptly discontinue therapy (risk of rebound hypertension).
Active hepatic disease, history of previous methyldopa-induced liver dysfunction, hemolytic anemia associated with methyldopa, anuria, hypersensitivity to methyldopa, chlorothiazide, or sulfonamide-derived drugs, severe renal impairment (Cr Cl <30 m L/min), and concomitant therapy with MAO inhibitors.
Avoid tyramine-rich foods (e.g., aged cheeses, cured meats, fermented products) due to risk of hypertensive crisis. Limit alcohol intake as it may enhance orthostatic hypotension.
Avoid high-potassium foods (bananas, oranges, spinach) unless specifically advised; chlorothiazide may cause potassium loss, but methyldopa can cause potassium retention. Avoid excessive alcohol intake as it may potentiate hypotension. Take with food to reduce gastrointestinal upset. May decrease glucose tolerance; monitor in diabetic patients.
FDA Pregnancy Category D. First trimester: increased risk of neural tube defects, cardiovascular anomalies, and cleft palate due to folate antagonism. Second and third trimesters: risk of oligohydramnios, fetal renal dysfunction, and premature closure of ductus arteriosus if used after 30 weeks gestation.
FDA Pregnancy Category D. First trimester: Associated with cardiovascular defects (e.g., VSD), neural tube defects, and oral clefts. Second and third trimesters: Fetal nephrotoxicity (oligohydramnios, renal failure), premature closure of ductus arteriosus, pulmonary hypertension, and intracranial hemorrhage. Avoid in third trimester.
Contraindicated during breastfeeding. M/P ratio: not determined. Excreted in human milk in low concentrations, but potential for serious adverse reactions in nursing infants, including hemolytic anemia and kernicterus due to sulfonamide component.
Chlorothiazide is excreted in breast milk; M/P ratio unknown. Can suppress lactation. Use only if maternal benefit outweighs potential infant risks (e.g., electrolyte disturbances, thrombocytopenia).
No established safe dose. Drug should be avoided during pregnancy. If unavoidable, use lowest effective dose for shortest duration. Trimethoprim component may require dose reduction due to increased glomerular filtration rate in pregnancy, but specific adjustment not validated. Sulfamethoxazole dose unchanged.
Increased volume of distribution and GFR in pregnancy may necessitate higher doses for equivalent effect. Start at lowest effective dose; titrate based on BP response. Monitor for hypokalemia and metabolic alkalosis.
Harmonyl is a brand name for deserpidine, a Rauwolfia alkaloid used as an antihypertensive. It depletes catecholamines and serotonin from central and peripheral nerve endings. Onset of action is 1-2 weeks. Avoid in patients with history of depression, peptic ulcer, or pheochromocytoma. Monitor for bradycardia and hypotension. May cause extrapyramidal symptoms. Use with caution with MAOIs; avoid concurrent use.
Aldoclor-250 is a combination of methyldopa (250mg) and chlorothiazide. Methyldopa can cause a positive direct Coombs test (10-20% of patients) which may interfere with blood cross-matching; obtain a hematocrit and Coombs test before therapy and at 6 and 12 months. Chlorothiazide may cause hypokalemia; monitor potassium and consider potassium supplementation. Onset of methyldopa is 3-6 hours; delay full effect for 48-72 hours. Avoid use in patients with active liver disease or history of previous methyldopa-induced liver dysfunction.
Take this medication exactly as prescribed, usually once daily.,Do not stop taking this medication abruptly; sudden withdrawal can cause severe hypertension.,You may experience dizziness or drowsiness; avoid driving or operating machinery until you know how the medication affects you.,Avoid alcohol while taking this medication.,Report any signs of depression, unusual mood changes, or difficulty sleeping to your doctor.,If you have a history of stomach ulcers, inform your doctor before starting this medication.,Keep all appointments for blood pressure monitoring.
Take exactly as prescribed; do not skip doses or stop suddenly.,May cause drowsiness or dizziness; avoid driving or operating machinery until you know how it affects you.,Rise slowly from sitting or lying to prevent lightheadedness.,Report any unexplained fever, jaundice, or dark urine immediately.,Use sun protection; this drug may increase sensitivity to sunlight.,Do not use potassium supplements or salt substitutes without consulting your doctor.,If you miss a dose, take it as soon as you remember unless it's near the next dose; do not double.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about HARMONYL vs ALDOCLOR-250, answered by our medical review team.
HARMONYL is a Antihypertensive that works by Harmonyl is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, leading to decreased peripheral vascular resistance and blood pressure.. ALDOCLOR-250 is a Antihypertensive Combination (Central Alpha Agonist and Thiazide Diuretic) that works by Aldoclor-250 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urinary output and reducing plasma volume.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HARMONYL and ALDOCLOR-250 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HARMONYL is: 25 mg orally once daily, taken with food. Maximum dose: 50 mg once daily.. The standard adult dose of ALDOCLOR-250 is: 250 mg orally twice daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between HARMONYL and ALDOCLOR-250 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. HARMONYL is classified as Category C. FDA Pregnancy Category D. First trimester: increased risk of neural tube defects, cardiovascular anomalies, and cleft palate due to folate antagonism. Second and third trimesters: . ALDOCLOR-250 is classified as Category C. FDA Pregnancy Category D. First trimester: Associated with cardiovascular defects (e.g., VSD), neural tube defects, and oral clefts. Second and third trimesters: Fetal nephrotoxici. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.